Nvidia (NASDAQ:NVDA) has quietly built a strategic investment portfolio not many investors are aware of targeting companies ...

November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies ...

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden ...

Issued on behalf of Aleen Inc. "Our current focus is on understanding how an analytical tool can responsibly support everyday well-being, while staying entirely outside the realm of diagnostic or ...

Dr. Sanjay Chawla challenges trillion-dollar AI hype, arguing for simple, affordable tools that run on today’s hardware to ...

Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...

Thank you for signing up! Did you know with a Digital subscription to Yorkshire Post, you can get access to all of our premium content, as well as benefiting from fewer ads, loyalty rewards and much ...

Understanding why you feel low when the seasons change, and how to gently reset your mind and mood. The post How to Recognise ...

Learn more about whether Nurix Therapeutics, Inc. or Recursion Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Wondering if Recursion Pharmaceuticals at around $4.83 is a beaten down bargain or a value trap? This breakdown walks through what the current market price is really implying. The stock has bounced ...

Recursion Pharma, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral ...